About: Preparation of recombinant vaccines

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Preparation of recombinant vaccines Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Preparation of recombinant vaccines
Creator	Houdebine, Louis-Marie Soler, Eric
Source	Elsevier; Medline; PMC
abstract	Vaccination is one of the most efficient ways to eradicate some infectious diseases in humans and animals. The material traditionally used as vaccines is attenuated or inactivated pathogens. This approach is sometimes limited by the fact that the material for vaccination is not efficient, not available, or generating deleterious side effects. A possible theoretical alternative is the use of recombinant proteins from the pathogens. This implies that the proteins having the capacity to vaccinate have been identified and that they can be produced in sufficient quantity at a low cost. Genetically modified organisms harboring pathogen genes can fulfil these conditions. Microorganisms, animal cells as well as transgenic plants and animals can be the source of recombinant vaccines. Each of these systems that are all getting improved has advantages and limits. Adjuvants must generally be added to the recombinant proteins to enhance their vaccinating capacity. This implies that the proteins used to vaccinate have been purified to avoid any immunization against the contaminants. The efficiency of a recombinant vaccine is poorly predictable. Multiple proteins and various modes of administration must therefore be empirically evaluated on a case-by-case basis. The structure of the recombinant proteins, the composition of the adjuvants and the mode of administration of the vaccines have a strong and not fully predictable impact on the immune response as well as the protection level against pathogens. Recombinant proteins can theoretically also be used as carriers for epitopes from other pathogens. The increasing knowledge of pathogen genomes and the availability of efficient systems to prepare large amounts of recombinant proteins greatly facilitate the potential use of recombinant proteins as vaccines. The present review is a critical analysis of the state of the art in this field.
has issue date	2007-09-15(xsd:dateTime)
bibo:doi	10.1016/s1387-2656(07)13004-0
bibo:pmid	17875474
has license	no-cc
sha1sum (hex)	b4836dd3cbf15de2b367758599de518338ed6a38
schema:url	https://doi.org/10.1016/s1387-2656%2807%2913004-0
resource representing a document's title	Preparation of recombinant vaccines
has PubMed Central identifier	PMC7106376
has PubMed identifier	17875474
schema:publication	Biotechnol Annu Rev
resource representing a document's body	covid:b4836dd3cbf15de2b367758599de518338ed6a38#body_text
is schema:about of	named entity 'adjuvants' named entity 'improved' named entity 'Multiple' named entity 'eradicate' named entity 'vaccination' named entity 'Adjuvants' named entity 'infectious diseases' named entity 'pathogens' named entity 'administration' named entity 'fact' named entity 'large' named entity 'Vaccination' named entity 'vaccines' named entity 'PURIFIED' named entity 'LARGE' named entity 'GENERALLY' named entity 'INFECTIOUS DISEASES' named entity 'CASE' named entity 'FACT' named entity 'EVALUATED' named entity 'USE OF' named entity 'SYSTEMS' named entity 'GENETICALLY MODIFIED ORGANISMS' named entity 'CONDITIONS' named entity 'EPITOPES' named entity 'ANIMALS' named entity 'GENERATING' named entity 'MICROORGANISMS' named entity 'ADJUVANTS' named entity 'STRONG' named entity 'THEIR' named entity 'CAPACITY' named entity 'LIMITS' named entity 'BASIS' named entity 'INACTIVATED' named entity 'ART' named entity 'GENES' named entity 'THEORETICAL' named entity 'TRANSGENIC PLANTS' named entity 'IMMUNIZATION AGAINST' named entity 'PATHOGENS' named entity 'RECOMBINANT VACCINE' named entity 'AMOUNTS' covid:arg/b4836dd3cbf15de2b367758599de518338ed6a38 named entity 'PREPARATION' named entity 'ANIMAL CELLS' named entity 'MULTIPLE' named entity 'LIMITED BY' named entity 'VACCINATION' named entity 'CONTAMINANTS' named entity 'GREATLY' named entity 'PATHOGEN' named entity 'VARIOUS' named entity 'POSSIBLE' named entity 'FIELD' named entity 'PROTECTION' named entity 'SIDE EFFECTS' named entity 'MODE' named entity 'ADMINISTRATION' named entity 'NOT AVAILABLE' named entity 'ALTERNATIVE' named entity 'RECOMBINANT VACCINES' named entity 'APPROACH' named entity 'VACCINATING' named entity 'ANALYSIS' named entity 'PROTEINS' named entity 'TO PREPARE' named entity 'IS A' named entity 'TO AVOID' named entity 'CRITICAL' named entity 'REVIEW' named entity 'HUMANS' named entity 'LEVEL' named entity 'USED' named entity 'FULLY' named entity 'STRUCTURE' named entity 'HAVE' named entity 'KNOWLEDGE' named entity 'IMMUNE RESPONSE' named entity 'THESE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software